Suppliers

Virpax announces completion of pre-IND meeting for its intranasal enkephalin

Virpax Pharmaceuticals has announced the successful completion of a pre-IND meeting with the FDA regarding the company’s NES100 intranasal enkephalin formulation for the management of acute and chronic pain. NES100 is a molecular envelope technology (MET) formulation licensed from Nanomerics and is delivered via a cartridge-based device.

In January 2020, Virpax announced that it also planned to develop intranasal enkephalin for the treatment of post traumatic stress disorder (PTSD).

Virpax Chairman and CEO Anthony P. Mack commented, “We are very pleased with the outcome of the pre-IND meeting with the FDA. The initial pathway to move forward with the development of NES100 has been clarified and confirmed.”

Read the Virpax Pharmaceuticals press release.

published on

March 4, 2020

Featured event:

Upcoming Events
Sponsored by Intertek,, hosts of
The Inhaled & Nasal Biologics | DNA Forum

Want information about upcoming OINDP-related events delivered directly to your inbox? click here

July 13-July 16: 2026 ISAM Congress, Taipei, Taiwan

September 15-September 18: DDL New Researcher Network Summer Event, London, UK

September 16-September 17: IPAC-RS 2026 Nasal Innovation Forum, Jersey City, NJ, USA

September 24-September 25: Inhaled & Nasal Biologics | DNA Forum, Cambridge, UK

October 14-October 15: Advancing Bioequivalence Frameworks for Inhalation and Nasal Drug Products: Optimizing In Vitro, In Vivo, and In Silico Methods, Rockville, MD, USA

See all upcoming events

Suppliers